📝 Sudeep Pharma Limited — results explained
Quarter ended June 2026 (Q1 FY27)
Sudeep Pharma Limited reported revenue of ₹106 crore for the quarter ended June 2026 (Q1 FY27), up 32.1% from ₹80 crore in the same quarter last year, and up 32.1% sequentially over the March 2026 quarter.
Net profit rose 35.3% year-on-year to ₹34 crore, from ₹25 crore. Earnings per share (EPS) came in at ₹3.00.
Operating profit stood at ₹39 crore — an operating margin (OPM) of 37.1%, compared with 37.5% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Sudeep Pharma Limited posted revenue of ₹338 crore, with a net profit of ₹108 crore.
On a trailing-twelve-month (TTM) basis, revenue stands at ₹364 crore with a net profit of ₹117 crore.
Valuation snapshot
At the current price of ₹1,000.70, SUDEEPPHRM has a market capitalisation of ₹11,303 crore and a trailing P/E of about 97.0.
Within the Pharmaceuticals industry, it is the largest of the 82 companies we track by market value.
Shareholding pattern
As of Sep 2026, promoters held 76.15%, foreign institutional investors (FIIs) 2.93%, domestic institutional investors (DIIs) 14.05%, public shareholders 6.87% of Sudeep Pharma Limited.